USA
Outside the US
Healthcare
Professionals Patients
Customer Portal
Logo
Menu
USA
Customer Portal
Outside the US

Now available
for DLBCL

The first Medicare-reimbursed MRD
assay for patients with DLBCL,
available as a CLIA-validated LDT.

$0 cost for Medicare patients—and with
no frequency restrictions.

LEARN MORE

Product Inquiry

Make a product inquiry request

Have a question about clonoSEQ®? Fill out the form below

    By submitting this form, I confirm that I am requesting medical information and certify that I am a physician and healthcare provider and that I am not submitting any patient information. I acknowledge and confirm that I have had an opportunity to read and understand the Adaptive Online Privacy Policy, Terms of Use, the HIPAA Notice, and other Adaptive online policies.



    Questions about a patient report or clonoSEQ results?

    Contact our Clinical Services team at 1 (888) 552-8988.

    Questions about the Adaptive Assist™ Patient Support program or billing?

    Call 1 (855) 236-9230, Monday through Thursday, 9 AM to 7 PM; and Friday, 9 AM to 5 PM ET.

    This page is intended for a US-based audience.

    clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.